Cite
HARVARD Citation
Concin, N. et al. (n.d.). 2022-RA-459-ESGO UPLIFT (ENGOT-ov67/GOG-3048) a registrational trial of Upifitamab Rilsodotin (XMT-1536; UpRi), a NaPi2b-directed antibody drug conjugate (ADC) in platinum-resistant ovarian cancer. International journal of gynecological cancer. p. A237. [Online].